Randomized trial shows mepolizumab reduces flares in patients with hypereosinophilic syndrome, indicating its effectiveness.
Compared with placebo, mepolizumab significantly reduced the occurrence of flares in patients with HES, with no new safety signals identified.
No takes yet. Share an insight, caveat, or question.
Roufosse et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: